Pre-filled syringe 60mg, 90mg, 120mg (Depot)

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Patients should be reviewed within 4 weeks of initiation of somatostatin analogues. Continuation of treatment should only be recommended if clinicians judge that patients have derived a meaningful response from somatostatin treatment (reduced stoma output, stool volume and progression towards closure of fistulas).

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment should only be continued if an adequate response is achieved (e.g. a 50% reduction in the need for transfusion or parenteral iron).

 For orthostatic intolerance disorders - IFR needed.

Injection 50 microgram/1mL, 1mg/5mL (multidose vial)

For use in Bowel obstruction in palliative care, please see chapter 21.

Depot injection 10mg, 20mg, 30mg

Consultant specialist initiation only.

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Patients should be reviewed within 4 weeks of initiation of somatostatin analogues. Continuation of treatment should only be recommended if clinicians judge that patients have derived a meaningful response from somatostatin treatment (reduced stoma output, stool volume and progression towards closure of fistulas).

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment should only be continued if an adequate response is achieved (e.g. a 50% reduction in the need for transfusion or parenteral iron).

 For orthostatic intolerance disorders - IFR needed.